We have previously reported the cardioprotective effects of endothelial progenitor cell (EPC)-conditioned media (CM) therapy post-myocardial infarction (MI).

Chronic heart failure after ST-segment elevation myocardial infarction (MI) remains a public health burden despite current percutaneous interventional and pharmacological treatment. Strategies to reduce infarct size are needed but remain a therapeutic challenge. We have examined the potency of cytokines identified in CM in a clinically relevant setting with promsing results, showing that a 1-time bolus of therapy has potent acute cardioprotective effects, activation of classic prosurvival signaling pathways and that acute cell salvage translates into long-term preservation of cardiac structure and function without the significant side effects seen in previous trials. These data suggest that our therapy may be a useful adjunctive agent for acute MI.